Mohammad Doroudian
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- MicroRNA in disease regulation 8
-
- Advanced Drug Delivery Systems 4
- Co-authors
- Seamas C. DonnellyElaheh MovahedRonan MacLoughlinLeona MawhinneyCiaran O’ReillyAdriele Prina‐MelloMohsen MoghoofeiFatemeh Farjadian
- Journals
- Critical Reviews in Oncology/Hematology (3 papers)Pharmaceutics (3 papers)Reviews in Medical Virology (3 papers)Advanced Therapeutics (3 papers)QJM (2 papers)
- Partner nations
- IranIrelandUnited States
In The Last Decade
Mohammad Doroudian
48 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Cancer Research 365
- Biomaterials 195
- Immunology 297
- Pharmaceutical Science 79
- Molecular Biology 831
Countries citing papers authored by Mohammad Doroudian
This map shows the geographic impact of Mohammad Doroudian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Doroudian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Doroudian more than expected).
Fields of papers citing papers by Mohammad Doroudian
This network shows the impact of papers produced by Mohammad Doroudian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Doroudian. The network helps show where Mohammad Doroudian may publish in the future.
Co-authors
The 25 scholars most cited alongside Mohammad Doroudian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 24 | |
| 2 | 2024 | 25 | |
| 3 | 2024 | 10 | |
| 4 | 2024 | 39 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 32 | |
| 7 | 2023 | 13 | |
| 8 | 2023 | 6 | |
| 9 | 2023 | 49 | |
| 10 | 2023 | 13 | |
| 11 | 2022 | 39 | |
| 12 | 2022 | 16 | |
| 13 | 2022 | 37 | |
| 14 | 2021 | 49 | |
| 15 | 2021 | 53 | |
| 16 | 2021 | 98 | |
| 17 | 2021 | 20 | |
| 18 | 2021 | 24 | |
| 19 | 2020 | 25 | |
| 20 | The Novel Study of IMODTM against HIV-1, P24 production | 2011 | 1 |
About Mohammad Doroudian
Mohammad Doroudian is a scholar working on Cancer Research, Pharmaceutical Science, Biomaterials, Business and International Management and Infectious Diseases, having authored 49 papers that have together received 1.6k indexed citations. Recurring topics across this work include Extracellular vesicles in disease (10 papers), MicroRNA in disease regulation (8 papers), Nanoparticle-Based Drug Delivery (7 papers), Nanoplatforms for cancer theranostics (7 papers), RNA Interference and Gene Delivery (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Advanced Drug Delivery Systems (4 papers) and Circular RNAs in diseases (4 papers). The work is most often cited by research in Cancer Research (365 citations), Biomaterials (195 citations), Immunology (297 citations), Pharmaceutical Science (79 citations) and Molecular Biology (831 citations). Mohammad Doroudian has collaborated with scholars based in Iran, Ireland and United States. Frequent co-authors include Seamas C. Donnelly, Elaheh Movahed, Ronan MacLoughlin, Leona Mawhinney, Ciaran O’Reilly, Adriele Prina‐Mello, Mohsen Moghoofei, Fatemeh Farjadian, Javid Sadri Nahand and Fergus E. Poynton. Their work appears in journals such as Critical Reviews in Oncology/Hematology, Pharmaceutics, Reviews in Medical Virology, Advanced Therapeutics and QJM.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.